SanaBio

Sana Biotechnology is a clinical-stage biotechnology company focused on creating and delivering engineered cells as medicines. The company leverages two primary technology platforms: the Hypoimmune (HIP) platform, designed to create cells that can evade the immune system for off-the-shelf use, and the Fusogen platform, which enables cell-specific delivery of genetic payloads in vivo. Their lead programs include SC291, a hypoimmune-modified CD19-targeted CAR-T therapy for B-cell malignancies and autoimmune diseases, and UP421, an islet cell therapy for Type 1 Diabetes. Sana aims to address a wide range of diseases with high unmet needs, including cancers, diabetes, and central nervous system disorders, by replacing or repairing damaged cells. The company is headquartered in Seattle and is publicly traded on the Nasdaq under the symbol SANA.